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Nucleic acid ampliﬁcation tests for Mycobacterium tuberculosis (MTB) detection from sputum are highly
sensitive and speciﬁc with smear microscopy positive specimens, but their sensitivity with smear-
negative/culture-positive specimens is much lower; therefore, these tests cannot rule out a tubercu-
losis diagnosis. Co-extraction of PCR inhibitors may be a cause of decreased test sensitivity. Here the
design and early validation of a MTB screening assay with sample preparation and qPCR methods
designed to speciﬁcally address this diagnostic gap is reported. First, human genomic DNA is identiﬁed as
a signiﬁcant qPCR inhibitor. To circumvent this problem, a novel, streamlined sample preparation
method utilizing detergent and proteolysis to thin the sputum and DNA sequence speciﬁc MTB DNA
isolation was developed. Additionally, a multiplexed qPCR assay targeting two MTB complex-speciﬁc
loci: the potentially multi-copy IS6110 and the single-copy senX3-regX3, combined with the cotJC gene
from Bacillus atrophaeus spores ampliﬁed as a process control was developed. The limit of detection of
the test was estimated to be 20 cfu/ml which is signiﬁcantly lower than the Xpert® MTB/RIF assay. In a
preliminary ﬁeld study of 60 de-identiﬁed blinded sputa, a test sensitivity of 96% and speciﬁcity of 100%
was observed when compared to the Xpert® MTB/RIF assay.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB)
complex species, is the deadliest infectious disease globally with an
estimated 9.6 million people falling ill, and 1.5 million people dying
from TB in 2014 [1]. HIV-1 positive populations are particularly
susceptible to TB and are 29 times more likely to die from active TB
disease than HIV-1 negative populations. HIV-TB coinfection con-
tributes substantially to TB-associated deaths worldwide, as 1.2
million (12%) individuals who developed TB were HIV positive, and
0.4 million co-infected patients died in 2014, accounting for 27% of
the estimated 1.5 million deaths from TB [1]. Accurate and timely
diagnosis is the ﬁrst step in providing care to patients and pre-
venting transmission.
Mycobacterial culture has long been the conventional gold
standard test for TB diagnosis in high resource settings. It has highMcFall).
Ltd. This is an open access article usensitivity (limit of detection ~10 cfu/ml) [2] but the time-to-result
is lengthy (ranging from 2 to 8 weeks) [3] and the sample prepa-
ration is technically challenging, prone to contamination and re-
quires a BSL-3 laboratory facility. In most low resource settings,
bacterial culture is unavailable, leaving sputum smear microscopy
as the only direct bacteriological test available [4]. The limit of
detection (LOD) of the unconcentrated smear test is approximately
10,000 cfu/ml, and it has poor speciﬁcity in settings where non-
tuberculosis mycobacteria are commonly isolated [3]. Smear
microscopy's poor clinical performance is particularly troublesome
in settings with high HIV-1 incidence. The HIV-1 epidemic has led
to a disproportionate increase in the reported rate of smear-
negative TB patients, and co-infection with HIV-1 changes the
presentation of smear-negative TB to more rapidly progressive
disease with a high mortality rate [5,6].
Nucleic acid ampliﬁcation tests (NAT) have the potential to
provide highly sensitive detection of paucibacillary forms of
tuberculosis with rapid turn-around-time; however, the commer-
cially available NATs are not yet meeting this need. To date, the
analytical sensitivity of the most widely adopted NAT, the Xpert®nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ml sputum (95% CI) which is only slightly less sensitive than culture
(10e100 cfu/ml), and the qPCR assay LOD is < 4.5 genomes per
reaction [7]. The clinical sensitivity with smear-positive specimens
is 98% when compared to culture; however, clinical sensitivity with
smear-negative specimens is only 67% [8]. This sensitivity can be
improved to greater than 90% by testing the same patient 3 times
[7]. Suboptimal sensitivity is likely to lead to reduced test impact, as
clinicians will continue to use empiric treatment in test-negative
patients [9] or alternatively may miss the diagnosis of TB in pa-
tients with paucibacillary TB, such as children and people living
with HIV.
The performance of MTB NATs is greatly impacted by the sample
preparation, mycobacterial lysis, and DNA extraction methods uti-
lized [10,11]. Leung et al. [12] reported up to a 12.5-fold difference
in DNA yield simply due to different cell lysis and DNA extraction
protocols. Additionally, biological factors in sputum can cause PCR
inhibition with a reported 5-fold decrease in analytical sensitivity
of an MTB-speciﬁc PCR assay when comparing extraction from
buffer to sputum [13]. Indeed, sputum appeared to be one of the
more difﬁcult sample type for detecting MTB using the Xpert®
MTB/RIF test because pulmonary specimens had a greater propor-
tion of inhibited samples as measured by the Cq of internal process
control of the than non-pulmonary sample types (6% vs. 1%) [14]. In
a large study of 741 patients, 15.5% of the Xpert® MTB/RIF positive
specimens were inaccurately quantiﬁed due to PCR inhibition
observed by substantial delays in the internal control values [15],
and in another smaller study, ~20% of false negatives were reported
to be caused by the presence of Taq inhibitors from sputum [16].
The sensitivity gap between culture and NAT performance implies
that an analysis of the different sample preparation and testing
methods may reveal strategies that can improve NAT performance
to approach that of culture.
MTB NAT sample preparation can be performed by concen-
trating and purifying intact MTB from sputum, or by directly lysing
MTB bacteria in sputum followed by extraction of DNA. MTB in
liqueﬁed sputum can be concentrated through centrifugation fol-
lowed by resuspension of the pellet in buffer, or MTB can be puri-
ﬁed through ﬁltration and washing as in the Xpert®MTB/RIF Assay
[17]. However, logistical obstacles often thwart successful execu-
tion of these established sample processing methods. The sample
volume of sputum is generally limited because the high concen-
tration of PCR inhibitors and nucleases found in the specimen can
cause assay failure. Sputum itself is a viscous, heterogeneous
mixture that contains high levels of nucleic acid, and concentrating
by ﬁltration limits the test volume because the ﬁlter will readily
clog. Tests that rely on centrifugation to concentrate the bacilli from
the liqueﬁed sputum also neglect the free MTB DNA present in the
supernatant [18], which may reduce the overall sensitivity of the
assay.
Here a MTB screening assay is described with a novel sample
preparation method that achieves an LOD of 20 cfu/ml which is
more sensitive than the current NATs and approaches that of cul-
ture. Human genomic DNAwas identiﬁed as the key qPCR inhibitor
present in sputum, and a sample preparation method was devel-
oped that substantially eliminates it from the ampliﬁcation reac-
tion. A multiplexed qPCR assay was also developed that targets two
M. tuberculosis complex (MTBC)-speciﬁc loci to increase sensitivity
and minimize the likelihood of false negatives due to target gene
mutation or deletion. It includes the potentially multi-copy inser-
tion sequence IS6110 [19], and the highly conserved single-copy
backup target senX3-regX3, a mycobacterial two-component regu-
latory operon critical for MTB virulence [20]. Ampliﬁcation of the
cotJC gene in Bacillus atrophaeus spores, which are added to the rawsputum, serves as a control for adequate processing of the target
bacteria and to monitor qPCR inhibitors. The effectiveness of the
sequence speciﬁc sample preparation method was veriﬁed with 60
sputum specimens collected from symptomatic TB patients dis-
playing 96% sensitivity and 100% speciﬁcity compared to the Gen-
eXpert® MTB/RIF Assay.
2. Materials and methods
2.1. Bacterial strains, genomic and plasmid DNA and sample sources
Two MTBC strains, M. tuberculosis H37Ra and Mycobacterium
bovis BCGwere acquired from the American Type Culture Collection
(ATCC; Manassas, VA) and used as positive controls for assay
development. Mycobacterial samples were sonicated to break up
cell clumps prior to contriving sputum specimens as described by
Helb et al. [7]. B. atrophaeus spores (MesaLabs; Lakewood, CO) were
used as the process control. M. tuberculosis H37Rv TMC 303
genomic DNA (ATCC; Manassas, VA) was used as the template for
DNA-speciﬁc capture and real-time PCR assays. Genomic DNA from
6 Mycobacterium species: Mycobacterium gordonae, Mycobacterium
intracellulare, Mycobacterium terrae, Mycobacterium malmoense,
Mycobacterium celatum, and Mycobacterium abscessus (ATCC;
Manassas, VA) was used as the template for the speciﬁcity panel.
The b -globulin plasmid used to generate a standard curve of the
human single-copy b -globulin gene, HBB [21], was constructed by
cloning 476 bp of nucleotide 76e552 of the HBB sequence
(sequenceID:gblKP309822.1) into the EcoR1 site of pGEM(R)-T Easy
Vector (Promega; Madison, WI). Residual sputum specimens were
obtained from TriCore Reference Laboratories (Albuquerque, NM)
in frozen 1 ml aliquots.
2.2. Quantitative PCR
PCR master mix for a 25 ml total reaction volume (15 ml master
mix and 10 ml of eluted DNA) consisted of: 0.2 mg/ml bovine serum
albumin (BSA; Life Technologies Corporation; Grand Island, NY),
0.2% tween-20, 150 mM trehalose (Sigma; St. Louis, MO), 10%
glycerol, 62.5 mM bicine pH 8 (Affymetrix; Santa Clara, CA),
135 mM potassium acetate pH 7.5 (Affymetrix; Santa Clara, CA),
1.5 mMmanganese chloride (Sigma; St. Louis, MO), 0.325 mM each
dNTP (Life Technologies Corporation; Grand Island, NY), 3.75 U
RMS Z05 DNA polymerase (Roche Molecular Systems, Inc.,
Branchburg, NJ), and sequence-speciﬁc oligonucleotides (Table 1).
For the IS6110 single-plex assays, 200 nM IS6110 F7, 200 nM IS6110
R10, and 300 nM IS6110 probe were used. For the b-globulin assays,
100 nM bgF, 100 nM bgR and 150 nM b-globulin probe were used.
For the multiplexed MTB assay, 200 nM IS6110 F7, 200 nM IS6110
R10, 300 nM IS6110 probe, 300 nM senX3-regX3 F3, 200 nM senX3-
regX3 R2, 200 nM senX3-regX3 probe 8, 100 nM cotJC F2, 100 nM
cotJC R2 and 100 nM cotJC probe3. Freeze-dried qPCR master mix
was used for the DNase I experiment and for the ﬁeld testing study
using clinical specimens. The freeze-dried master mix composition
is the same as the liquid qPCRmastermix except that the amount of
qPCR enzyme stabilizers were modiﬁed as follows: 2.5 mg/ml BSA,
0.03% tween-20 and 138 mM trehalose, and the bicine buffer, po-
tassium acetate and manganese were not freeze dried rather they
were added as the resuspension buffer. Oligonucleotides were
supplied by IDT (Corvallis, IA) with the exception of the cotJC
probe3 which was supplied by Biosearch Technologies (Petaluma,
CA).
Ampliﬁcation was performed in a 5-plex Qiagen (Hilden, Ger-
many) Rotor-Gene Q thermocycler, with the following cycling
conditions: 1.95 C 2:00, 2.95 C 0:15, 3: 60 C 0:45, 4. repeat steps
Table 1
Oligonucleotides Table. þ indicates locked nucleic acid.
Gene Oligo Oligo sequence Reference
Human b -globulin bgF 50-GGCAGGTTGGTATCAAGGTTAC-30 [21]
Human b -globulin bgR 50-CCTAAGGGTGGGAAAATAGACC-30 [21]
Human b -globulin Bg Probe 50 Quasar 670e ACTGGGCATGTGGAGACAGA-BHQ2-dT 30 [21]
MTB IS6110 IS6110 F7 50-CGATGTGTACTGAGATCCCCTATCCG-30 This study
MTB IS6110 IS6110 R10 50-GGCCTTTGTCACCGACGCC-30 This study
MTB IS6110 IS6110 FAM 50/56-FAM/AACGTCTTT/ZEN/CAGGTCGAGTACGCCTT/3IABkFQ/-30 This study
MTB senX3-regX3 senX F3 50-CAGAGCGTAGCGATGAGGTGG-30 This study
MTB senX3-regX3 senX R2 50-GCCTCAAAGCCCTCCTTGCG-30 This study
MTB senX3-regX3 senX probe 8 50-/5HEX/GAGGAþCGAGGAGTþCGCþTGGC/3BHQ_1/-30 This study
BA cotJC cotJC F2 50-GGCGGCTCTTCGTTACTTAAA-30 This study
BA cotJC cotJC R2 50-GAACTCCTCGGTCCCTATATCA-30 This study
BA cotJC cotJC probe 3 5’-/d Quasar 670/TACCTGACAAAGTGATCGGGCTGC/BHQ_2/-30 This study
Gene Capture probe Oligo sequence Reference
MTB IS6110 Cap-1 50-Biotin-AAAAACGAACGGCTGATGACCAAACTC-30 [22]
MTB IS6110 Cap-2 50-Biotin-AAAAAGGAGGTGGCCATCGTGGAAG-30 [22]
MTB senX3-regX3 SENX CAP 3 50-Biotin- AAAAACCAGTGTGTTGATTGTGGAGGACGAG-30 This study
MTB senX3-regX3 SENX CAP 4 50-Biotin-AAAAAGTGGAATCAAAGCCCTCCTTGCG-30 This study
BA cotJC cotJC Cap 1 50-Biotin-AAAAACAAATACTTAATCGAGCAATATGGCGGCG-30 This study
BA cotJC cotJC Cap 2 50Biotin-AAAAAGCTTATACACCATCGTCGCAATCATCTCC-30 This study
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red channels, and copy number of the two MTB targets, relative to
the H37Rv TMC 303 genomic DNA standard curve, was determined
by using the Qiagen Rotor-Gene Q Series Software package.2.3. Detection of qPCR inhibition
The presence of inhibitors which caused discordant qPCR results
was examined by preparing and amplifying 10-fold dilutions of the
eluates and comparing the quantiﬁcation cycles (Cqs) of the diluted
vs. the undiluted samples. Assuming a 100% efﬁcient qPCR assay,
the Cqs should be 3.3 cycles apart. A semi-quantitative inhibition
rating (IR) was established based upon dCq, the difference between
expected Cq and the actual Cq. A dCq less than 1 was represented
by a score of IR ¼ 0 (uninhibited); dCq between 1 and 3 was rep-
resented by a score of IR ¼ 1 (moderately inhibited); and dCq
greater than 3 or reaction failure was represented by a score of
IR ¼ 2 (severely inhibited).2.4. DNase I treatment
A cocktail of sputum specimens was prepared by vortexing 15
1 ml residual sputum specimens with approximately 7.5 g acid-
washed 5 mm glass beads (Sigma; St. Louis, MO) for 5 min. Five
aliquots of 350 mls each were extracted using the Dynabeads®
SILANE Genomic DNA Kit (Life Technologies, Carlsbad, CA) as per
manufacturer instructions, and the elutions were pooled. 11.5 ml of
the pooled eluate was treated with 1 ml Turbo DNase I (Life Tech-
nologies, Carlsbad, CA), 1.5 ml Turbo DNase I buffer, and 1 ml mo-
lecular grade water in a total of 15 ml and incubated for 30 min at
37 C followed by 20 min at 95 C to inactivate the DNase I. The
controls for this study included heat inactivated DNase I treated
eluate, untreated eluate, elution buffer and elution buffer plus
DNase I buffer. For the heat inactivated DNase I control, Turbo
DNase I was ﬁrst inactivated for 20min at 95 C, and then combined
with the eluted DNA and Turbo DNase I buffer as described above.
Fifteen microliters of the untreated eluate, elution buffer and
elution buffer plus DNase I buffer were added directly to the PCR
reaction. Five thousand copies of H37Rv MTB genomic DNA was
ampliﬁed PCR using the MTB IS6110 assay.2.5. Sputum thinning and extraction method comparison
Three different sputum thinning and decontamination methods
were compared with 16 individual sputum specimens (Figure 3A):
N-acetyl-L-cysteine-sodium hydroxide (NALC), guanidinium hy-
drochloride (GuHCl) which is the ﬁrst step of the Dynabeads®
SILANE Genomic DNA Kit (Life Technologies, Carlsbad, CA), and
sodium dodecyl sulfate with proteinase K (SDS/PK). The NALC-
NaOH and GuHCl treated samples were subsequently extracted
using the Dynabeads® SILANE Genomic DNA Kit, and the SDS/PK
treated samples were extracted using DNA sequence speciﬁc cap-
ture. One million cfu of M. bovis BCG was added to each test.
Human DNA was quantiﬁed using a standard curve of 100 to
1,000,000 copies of b-globulin plasmid DNA. MTB yield was quanti-
ﬁed via a standard curve of 100 to 100,000 copies of IS6110 M. bovis
BCG genomic DNA. Samples were run at 10 ml eluate, 10 ml of 101
dilution and 10 ml of 102 dilution in duplicate to insure that the Cq
would be on the standard curve and to use the dilutions to determine
if ampliﬁcationwas inhibited. For the GuHCl samples, the b-globulin
gene was quantiﬁed using the 102 dilution and determined the in-
hibition by comparing the Cqs of the 101 and 102 dilutions. For the
NALC treated samples, the b-globulin gene was quantiﬁed using the
101 dilutions anddetermined inhibition bycomparing the Cqs of the
neat samples vs. the 101 dilutions. For the SDS/PK treated samples,
the b-globulin gene was quantiﬁed using the neat eluates and deter-
mined inhibition by comparing the Cqs of the neat samples vs. the
101 dilutions. For IS6110, all 3 conditions, GuHCl, NALC and SDS/PK
werequantiﬁedusing the101dilutions, and inhibitionwas identiﬁed
by comparing the Cqs of the neat eluates vs. the 101 dilutions.2.5.1. Sequence speciﬁc capture
A protocol for thinning and decontaminating sputum with
proteinase K, SDS and heat was developed to be compatible with a
DNA sequence speciﬁc capture method adapted from the protocol
published by Mangiapan et al. [22]. The reactions were performed
with dried sputum thinning and oligo hybridization reagents.2.5.2. Dried reagent tubes
Two tubes per reaction were prepared with dried reagents: one
for sputum thinning and the second for speciﬁc capture probe
(oligo) binding. The sputum thinning buffer was prepared by
combining 50 ml of 20% SDS, 30 ml of 1 M Tris, pH 8.0; 20 ml of 0.5 M
Figure 1. Development of qPCR assay for sample prep development and DNase I treatment of samples removes qPCR inhibition of IS6110 assay. (A) IS6110 qPCR assay. Standard
curve of 500,000; 50,000; 5000, 500, 50, and 5 MTB H37Rv genomic DNA copies in triplicate. The equation of the line is y ¼ 3.7X þ 35.5; R2 ¼ 0.997. qPCR efﬁciency ¼ 89%. (B)
Means diamonds plot of DNase I treated samples. Eluates from bulk sputum extractions were spiked into control qPCR assay to measure PCR inhibition. The center line of the
diamond is the mean. The tips of the diamond are the 95% conﬁdence interval and the lines near the tips indicate signiﬁcant differences if they don't overlap with other diamonds.
n ¼ 6 DNase I treated eluates, 3 DNase I buffer controls, 3 Tris buffer controls, and 6 untreated eluates. Heat-killed DNase I data not shown. 4 of 6 replicates failed to amplify.
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Figure 2. SDS/Proteinase K sputum thinning and sequence speciﬁc capture work ﬂow. 1. One ml sputum is added to sputum thinning tube containing dried reagents represented as
a black dot at bottom of tube. 2. Sputum is thinned at 55 C, organisms are lysed, and double-stranded DNA is melted at 95 C. 3. Thinned sputum is transferred to hybridization tube
containing dried reagents represented as a black dot at bottom of tube; 4. Within the hybridization tube, the oligos are hybridized to denatured MTB DNA target at 60 C; 5.
Streptavidin-coated PMPs capture biotinylated oligo-DNA complex; 6. The MTB DNA is eluted from the PMPs and subsequently ampliﬁed and detected using qPCR.
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30 mM Tris pH 8.0 and 10 mM EDTA, pH 8.0. One hundred micro-
liters of this SDS solution was pipetted on to the side of sterile
1.5 ml conical-bottom tubes; the tubes were kept in a horizontal
position and dried in a 55 C oven overnight. The oligo binding
buffer was prepared by combining 50 ml of 5 M NaCl, 10 ml of 1 M
Tris, pH 8.0, 2 ml of 0.5 M EDTA, pH 8.0 and 0.5 ml of 10% Tween-20
per reaction for a ﬁnal concentration of 250 mM NaCl, 10 mM Tris,
pH 8.0, 1 mM EDTA and 0.005% Tween-20. Sixty-two and one half
microliters of oligo binding buffer was pipeted on to the side of a
1.5 ml sterile conical tube and kept in a horizontal position while
dried in a 55 C oven overnight. After drying, the tubes were capped
and stored at room temperature in aluminum moisture-barrier
pouches (Ted Pella; Redding, CA), with silica gel desiccant
(McMaster Carr; Elmhurst, IL) to maintain dryness and a humidity
indicator card (Static Control Components; San Diego, CA) to
monitor moisture.
A cocktail of biotin-labeled oligonucleotides was prepared in
advance inwhich 5 ml contained a total of 5 or 5.5 pmol of probe: for
the singleplex IS6110 assay, 2.5 pmol of IS6110 capture probes 1 and
2were used, and for themultiplexed assay,1.25 pmol each of IS6110
capture probes 1 and 2, 1.25 pmol each of senX3-regX3 capture
probes 3 and 4, and 0.25 pmol each of cotJC capture probe 1 and
capture probe 2were used. All capture oligonucleotides contained a
50 end biotin moiety, included a spacer of 5 adenine residues prior
to the speciﬁc sequences described above, and were HPLC-puriﬁed.
Probes were obtained from Integrated DNA Technologies (IDT;
Coralville, IA), were diluted in 10 mM Tris pH 8, and stored
at 20 C until time of use.2.5.3. Sputum liquefaction, decontamination and lysis
To initiate sputum thinning, 950 ml sputum, 50 ml of Proteinase K
solution containing 30 U Proteinase K, and 1 ml 1 M CaCl2 wereadded to a 1.5 ml tube containing dried thinning reagent. The
samples were heated to 55 C for 8 min with mixing at 1000 rpm
(Benchmark Scientiﬁc, Inc; South Plainﬁeld, NJ). The temperature
was then ramped to 95 C, and the specimens were incubated for
10 min with 1000 rpm mixing.2.5.4. Speciﬁc capture based MTB DNA extraction
Samples were removed from the thermal mixer, spun brieﬂy,
and the entire volume was transferred to the tube containing dried
oligo binding buffer. Five microliters of biotin-labeled oligonucle-
otide cocktail mix (5 pmol in total) was added, and the samples
were incubated at 60 C and 1000 rpm for 20 min. Twenty micro-
liters of pre-washed Dynal Streptavidin M270 paramagnetic
particles (PMPs) (Thermo Fisher Scientiﬁc; Waltham, MA) were
added and samples were incubated for 10min at room temperature
with end-over-end rotation. The liquid was collected to the bottom
of the tube by a short centrifugation step and the PMPs were pel-
leted on a magnetic rack (DynaMag2™) for 2 min. Supernatants
were aspirated, the PMP pellet was resuspended in 1 ml wash
buffer (10 mM Tris, pH 8.0 & 0.01% Tween 20), and the entire
volume was transferred to a new 1.5 ml tube. Again, PMPs were
collected on a magnetic rack, followed by supernatant aspiration
and resuspension of PMPs in 1 ml wash buffer. Following this
second wash, PMPs were collected on the magnetic rack and the
supernatant was aspirated, taking care to remove all remaining
wash buffer volume. The pellet was carefully resuspended in 10 ml
elution buffer (10 mM Tris, pH 8.0 0.01% Tween 20, and 10% glyc-
erol) and heated at 75 C with 1500 rpm mixing, for 3 min. It is
important that PMPs are resuspended in the elution buffer during
the heated elution step. The liquid was collected at the bottom of
the tube by a brief spin, and the samples were placed on the
magnetic rack to collect PMPs. The 10 ml elution was carefully
transferred to clean tube ready for qPCR.
Sputum ≥ 1.80 ml 
(16 total)
350 μl
NALC
350 μl
GuHCl
1000 μl
SDS/PK (dried)
erutpaC cificepSerutpaC kluB
350 μl
**
A
B C
Figure 3. Impact of sputum thinning and DNA extraction methods on MTB IS6110 yield and the amount of co-extracted human genomic DNA. (A) Experimental design. 16 individual
sputum specimens were tested. (B) Means diamonds plot of human genomic DNA co-extracted with MTB DNA quantiﬁed via the HBB (b-globulin) gene. (C) Means diamonds plot of
IS6110 DNA captured. The center line of the diamond is the mean. The tips of the diamond are the 95% conﬁdence interval and the lines near the tips indicate signiﬁcant differences
if they don't overlap with other diamonds. Each group is represented by n ¼ 16.
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Prior to bulk DNA extraction using the Dynabeads® SILANE
Genomic DNA Kit, the sputum specimens were either thinned by
NALC treatment or by the addition of GuHCl, as speciﬁed in the kit's
instructions. Fresh NALC reagent was prepared by adding equal
volumes of 4% NaOH and 2.9% sodium citrate with 0.5 g NALC per
100 ml NaOH/citrate solution [23]. To each sputum specimen, an
equal volume of the NALC reagent was added and mixed by vor-
texing, then incubated for 15 min at room temperature with
intermittent shaking. The samples were neutralized by the addition
of phosphate buffer [pH 6.8] at a ratio of 1: 1.5 (sample: phosphate
buffer) and mixed by vortexing. The pellet was collected via
centrifugation for 15 min at 3000  g, resuspended with 350 ml
phosphate buffer and immediately processed using the Dyna-
beads® SILANE Genomic DNA Kit according to the manufacturer's
instructions. The GuHCl thinned sputawere immediately processed
using the Dynabeads® SILANE Genomic DNA Kit according to the
manufacturer's instructions.2.6. Laboratory validation study
The Xpert® MTB/RIF Assay was used as the clinical standard
since South Africa has adopted Xpert® MTB/RIF Assay (Cepheid;
Sunnyvale, CA) testing on sputum samples as the standard ﬁrst-linetest for diagnosis of MTB, with MTB culture only performed on
selected samples. Sixty de-identiﬁed blinded sputum specimens
were tested; 27 were Xpert® MTB/RIF positive and 33 were Xpert®
MTB/RIF negative. One of the Xpert negative specimens was invalid
(no Cq in cotJC test).2.7. Statistical methods
JMP® software (SDS Institute; Cary, NC) was used to calculate
differences between means via one-way analysis of variance for
independent samples, as well as to generatemeans diamonds plots.
P-values of less than 0.01 were considered signiﬁcantly different.
Pearson correlation tests were used to generate R2 values to eval-
uate correlations between sputum-speciﬁc factors and MTB assay
inhibition.3. Results
3.1. IS6110 qPCR assay
The MTBC-speciﬁc potentially multi-copy insertion sequence
IS6110 [19] was selected as the genetic target for a qPCR assay to
determine the efﬁcacy of MTB DNA extraction protocols from
sputum. The primers and probes were designed with 100%
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available in the NCBI database. The assay was demonstrated to be
linear across at least 6 logs of concentration from 500,000 to 5
copies (Figure 1A) and could detect as few as 1 MTB H37Rv genome
6 out of 6 times (data not shown).
3.2. MTB extraction from sputum
Multiple investigators have reported that silica-based extraction
methods such as the Boom method [24] yield MTB DNA with less
PCR inhibition than alternative methods [12,25,26]. The Dyna-
beads® SILANE Genomic DNA Kit (Life Technologies, Carlsbad, CA)
protocol is designed to extract genomic DNA from 350 ml whole
blood using 50 ml paramagnetic particles (PMP), but input volume
can be adjusted to suit speciﬁc experimental needs. In order to
evaluate bulk DNA extraction, initial studies were performed with
350 ml contrived TB-positive sputum specimens with the intention
of ultimately scaling up the sample volume to 1 ml. However, in
extracting MTB DNA using this system, the qPCR results differed
markedly between independent sputum samples. By amplifying
10-fold dilutions of the eluted DNA and quantifying the yield using
a standard curve derived from serial dilutions of MTB H37Rv
genomic DNA, it was determined that the MTB DNA yield from the
Dynabeads® extraction was similar between samples, but qPCR
inhibition varied dramatically (data not shown). In order to identify
the potential source of inhibition, 7 sputum samples were evalu-
ated for: appearance (bloody, mucopurulent, etc.), density, viscos-
ity, protein levels and human genomic DNA levels and compared
these results to qPCR inhibition. Of these variables, only human
genomic DNA (gDNA) content correlated with inhibition
(R2 ¼ 0.985, Pearson correlation test). Three of the 7 samples dis-
played qPCR inhibition of greater than 1 Cq, and these 3 samples
also had high levels of co-extracted human gDNA as measured by
copy number of the single copy gene for b-globulin (data not
shown). The other four sputa tested had much lower b-globulin
copy number in the eluted sample and no evidence of qPCR
inhibition.
Co-extraction of high amounts of human gDNA was conﬁrmed
to be the source of inhibition by treating sputum-derived DNA el-
uates with Turbo DNase I for 1 h at 37 C, heat-inactivating the
enzyme and then adding the eluates or equal volume of controls to
qPCR assays containing 5000 genomic copies of H37Rv genomic
DNA. Relief of inhibition was observed in the specimens that were
treated with active DNase I (Figure 1B). The Tris buffer control had
an average Cq of 22.0 ± 0.1, and the untreated eluate from sputum
extraction had an average Cq of 26.0 ± 0.3. This four Cq delay would
lead to more than a 10-fold under-quantiﬁcation of the MTB bac-
terial load. Treatment of eluate with DNase I allowed a mean re-
covery of 5.4 Cq. DNase I activity was required for this relief of
inhibition because heat-inactivated DNase I did not improve
ampliﬁcation (data not shown). In fact, 4 of the 6 replicates incu-
bated with inactivated DNase I failed to amplify while the
remaining two samples had Cqs of 24.6 and 28.5, similar to the
untreated eluate. Eluates from 3 additional sputum extractions
gave analogous results with DNase I treatment (data not shown)
indicating that human genomic DNA in sputum is a frequent and
potent qPCR inhibitor.
3.3. Development of sequence speciﬁc capture method
To limit the co-extraction of human DNA from sputum speci-
mens as observed with bulk DNA extraction, a protocol to selec-
tively purify mycobacterial DNA was developed using sequence
speciﬁc capture. The protocol is divided into two phases (Figure 2):
1) sputum thinning and MTB lysis (steps 1e3) and 2) MTB DNAcapture (steps 4e6). The sputum is thinned to a pipettable con-
sistency and simultaneously sterilized with minimum operator
steps. The process involves treating with Proteinase K (PK) and
SDS with a subsequent incubation at 95 C for 10 min. The SDS acts
as an emulsiﬁer breaking up mucoid complexes by unfolding
proteins, and PK facilitates sputum thinning by digesting the
unfolded proteins. Heating to 95 C decontaminates the specimen
by killing MTB and other ﬂora present, while simultaneously
denaturing the PK and initiating the speciﬁc capture reaction
through melting the double stranded DNA in the specimen. The
thinned sputum is then transferred to a tube containing dried NaCl
and MTB-speciﬁc biotinylated oligonucleotides (capture probes)
where a two-step capture process using streptavidin-coated
paramagnetic particles (PMP) is performed. The high afﬁnity of
biotin and streptavidin allows for the biotinylated oligo-DNA
complex to be isolated from the thinned sputum solution for
washing. The eluted DNA is subsequently ampliﬁed and detected
using real-time PCR.
3.4. Sequence speciﬁc capture versus silica bulk DNA capture
Sixteen MTB-negative sputum specimens with sufﬁcient vol-
ume (1.8 ml) were selected for the study. MTB-spiked sputum
specimen were thinned in one of 3 ways: 1) NALC, 2) GuHCl, or 3)
SDS/PK, and 350 ml of the thinned sputa were extracted by either
Dynabeads® SILANE Genomic DNA Kit (NALC& GuHCl) or sequence
speciﬁc capture (SDS/PK) (Figure 3A). Human gDNAyield measured
in b-globulin copies (Figure 3B), MTB DNA yield measured in IS6110
copies (Figure 3C), and qPCR inhibition rating (IR) was determined
by comparing the ampliﬁcation of the straight eluate versus the
1:10 dilution of the eluate. By using the SDS/PK thinning technique
with MTB speciﬁc capture, the average amount of human genomic
DNA co-extracted was reduced 2.5 to 3.7 logs. Mean b-globulin
copy number co-extracted from 350 ml of sputumwas 6.2 ± 0.7 log
for NALC treatment, 7.4 ± 1.4 log for GuHCl treatment, and 3.7 ± 0.7
log for SDS/PK treatment. The IR was zero for all 16 of the NALC-
treated or SDS/PK-treated samples indicating no qPCR inhibition.
However, 75% (12/16) of the GuHCl treated specimens exhibited
qPCR inhibition with the amount of b-globulin co-extracted cor-
responding to qPCR inhibition (Figure 4). The mean b-globulin log
copy yield of GuHCl treated samples with an IR of 0 (5.9 ± 1.6) was
signiﬁcantly different (p < 0.01) from IR1 (7.8 ± 0.5) and IR2
(8.1 ± 0.4), but the mean yields of IR1 and IR2 were not signiﬁcantly
different.
The yield of MTB DNAwas measured using 101 dilutions of the
eluate to bypass the effect of qPCR inhibition discussed above.
There were no signiﬁcant differences between mean MTB yield of
the GuHCl treated specimens (4.7 ± 1.0 log copies), the NALC
treated specimens (4.1 ± 0.6 log copies), or the SDS/PK treated
specimens (4.1 ± 0.8 log copies). It was estimated that at least 1 ml
of sputum must be extracted and ampliﬁed in order to achieve
equivalent sensitivity to culture (10 cfu/ml) [2]. Because only 10%
of the eluate from a 350 ml specimen was added, roughly 30-fold
less specimen volume was used in this experiment than the
target 1 ml. If the average genomic DNA yield were multiplied by a
factor of 30, the average yield of b-globulin copies would increase
to 7.7 logs for NALC, 8.9 logs for GuHCl, and 5.2 logs for SDS/PK
thinning with speciﬁc capture extraction. The amount of co-
extracted b-globulin DNA in the NALC treated specimens would
then be equivalent to the average amount of DNA found in the
inhibited GuHCl specimens, suggesting that 1 ml NALC-treated
samples would also likely be inhibited. The SDS/PK treated speci-
mens average gDNA yield for 1 ml of sputum would still be below
the likely inhibited level. Due to the speciﬁc capture based DNA
extraction resulting in equivalent IS6110 copies (Figure 3B), but
Figure 4. Sputum processing using guanidinium hydrochloride results in high levels of co-extracted human DNA leading to MTB qPCR inhibition. Nominal/Ordinal Scatterplot with
Means Diamonds of qPCR inhibition ratings vs. co-extracted human DNA is shown, the tips of the diamond are the 95% conﬁdence interval, the lines near the tips indicate signiﬁcant
differences if they don't overlap with other diamonds, and the center line is the mean. n ¼ 4 IR ¼ 0, 6 IR ¼ 1, 6 IR ¼ 2.
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preferred nucleic acid extraction strategy for the MTB diagnostic
assay.3.5. Multiplexed qPCR assay
Since IS6110 is not present in some clinical strains [27], the
IS6110 assay was multiplexed with primers and probes speciﬁc to
an intergenic region in the two-component regulatory operon
senX3-regX3 [20]. An amplicon of the B. atrophaeus cotJC gene that
encodes a spore coat composition polypeptide [28] was also
included to monitor the test for extraction, qPCR inhibitors, and
ampliﬁcation efﬁciency. The B. atrophaeus spores were added to the
sputum prior to sample processing and were thinned and lysed
alongwith theMTB. Capture probeswere designed for each speciﬁc
target, tested in isolation and then in combination for optimal
speciﬁc MTB DNA extraction (Figure 5). Contrived sputum speci-
mens of 5000 cfu of MTB H37Ra and 500 B. atrophaeus spores in
triplicate were extracted using the speciﬁc capture MTB DNA
extraction method, and the multiplexed PCR assay was performed
to conﬁrm capture of multiple targets and assay performance. The
IS6110 amplicon had an average Cq of 24.8 ± 0.4, the senX3-regX3
had an average Cq of 28.7 ± 0.5 and the cotJC amplicon had an
average Cq of 32.1 ± 0.6 (Figure 5).
To estimate the limit of detection, 1 ml sputum specimens were
contrived containing 100, 50 or 20 cfu/ml, and six replicates of each
concentration were assayed. All 6 of the 50 and 100 cfu/ml speci-
mens were detected by both the IS6110 and senX3-regX3 assays.
Five of the 20 cfu/ml specimens were detected by the IS6110 assay,
and none of these samples were detected by the senX3-regX3 assay.
Therefore, the LOD of the combined assay was estimated to be
20 cfu/ml. One of the 20 cfu/ml samples was excluded from analysis
because the Cqs in both MTB assays were anomalously low. MTB
has a tendency to clump, and despite the fact that the bacterialpreparationwas sonicated to break up clumps before it was serially
diluted for contriving the sputum specimens; this sample may have
had a clump of bacteria. Six different Mycobacterium species were
also tested for potential cross reactivity. Genomic DNA extracted
from M. gordonae, M. intracellulare, M. terrae, M. malmoense,
M. celatum, andM. abscessuswas added to qPCR reactions at 50,000
copies/PCR reaction, and no ampliﬁcation was observed for any of
these species.3.6. Laboratory validation study of sputum processing and work
ﬂow
To determine if the SDS/PK sputum pre-treatment combined
with sequence speciﬁc capture is effective in processing clinical
specimens, a small-scale laboratory validation study was per-
formed at the routine TB diagnostic laboratory at Groote Schuur
Hospital, Cape Town, South Africa. A convenient sample of 60
blinded routinely collected specimens that had 1 ml of sputum
left over after GeneXpert® testing were assayed using the multi-
plexed MTB assay protocol described here; 27 Xpert® MTB/RIF
positive specimens and 33 negative specimens were analyzed. All
60 distinct sputum samples thinned to a pipetable liquid in the
sputum thinning step. Of the 27 positive specimens, three samples
were negative in senX3-regX3 assay and one of these same samples
was also negative in the IS6110 assay yielding a sensitivity of 88.9%
(24/27) and 96.3% (26/27), respectively (Table 2). One of the Xpert®
MTB/RIF negative specimens failed to amplify the cotJC gene and
was therefore considered an invalid result. The sample that was a
false negative, having failed in both the IS6110 and senX3-regX3
assays, was reported as a very low positive in the Xpert® MTB/RIF
assay. The 32 negative specimens with valid test results were also
negative in the IS6110 and senX3-regX3 assays, yielding 100%
speciﬁcity in both assays.
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Figure 5. Multiplexed IS6110, senX3-regX3 and cotJC assay of contrived sputum specimens containing 5000 cfu/ml H37Ra MTB and 500 B. atrophaeus spores. All 3 targets are
efﬁciently captured and ampliﬁed from sputum. Horizontal black line is threshold. Solid black line is IS6110. Dashed black line is senX3-regX3. Dark gray line is cotJC, and light gray
line is no template control (NTC).
Table 2
Summary of testing results of CIGHT MTB assay and Xpert® MTB/RIF assay.
senX ¼ senX3-regX3 intragenic region. One of the Xpert® MTB/RIF negative speci-
mens had an invalid test result yielding valid results for 59 specimens.
GeneXpert® MTB/RIF assay Sensitivity or speciﬁcity (CI)
Positive Negative
IS6110 positive 26 0 96.3% (79.1e99.8)
IS6110 negative 1 32 100% (86.7e100)
totals 27 32 59 valid results
senX positive 24 0 88.9% (69.7e99.1)
senX negative 3 32 100%
totals 27 32 59 valid results
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In this report, novel methods of sputum pre-treatment, extrac-
tion and ampliﬁcation were combined to address the many of the
challenges of MTB diagnosis. The pre-treatment method liqueﬁes
sputum and lyses cells without the dilution associated with liquid
solutions. It also results in a homogeneous distribution of MTB DNA
that eliminates potential sampling errors due to the bacilli's
buoyancy and tendency to clump and chain. The speciﬁc capture
extractionmethodminimizes co-extraction of human DNAwhich is
a major inhibitor of ampliﬁcation. By combining IS6110, a poten-
tially multi-copy target that is not present in all MTB strains, and
senX3-regX3, a single-copy target in a genetic locus that is essential
for virulence [29], an assay was created that will detect all MTBC
strains with high sensitivity. A preliminary estimate of the LOD is
20 cfu/ml for the combined assay which is more than 6-times lower
than the LOD of the leading commercial test, Xpert®MTB/RIF which
is reported as 131 cfu/ml [7].
In order to achieve this high sensitivity, potential sputum-
derived factors that could contribute to assay inhibition were
methodically evaluated and human genomic DNAwas identiﬁed as
a major contributor to MTBC-speciﬁc qPCR assay inhibition.Furthermore, high amounts of human genomic DNA could have a
secondary technical effect of making the PMPs sticky, leading to
greater co-extraction of inhibitors from either the biological spec-
imen or DNA extraction solvents such as guanidinium or alcohols.
Guanidinium hydrochloride treated sputum yielded the highest
levels of co-extracted human DNA among the three DNA extraction
methods tested, as reﬂected by the single-copy human gene b-
globulin, as well as strongest assay inhibition.
In this study, one ml sputum specimen was introduced into the
tube containing dried sputum thinning reagent for sputum lique-
faction and decontamination. In this regard, the sample prep
strategymimics the processing of sputum for mycobacterial culture
growth, but the cumbersome sample neutralization and centrifu-
gation steps have been eliminated. This strategy also addresses the
biohazard risk associated with inadequate management of infec-
tious samples and the limitations of sample preparationmethods to
enhance the overall sensitivity of the assay. Sputum collection and
manipulation from putative TB patients puts healthcare workers at
risk for infection [30,31], and, for NAT testing in settings without
biosafety precautions, it is necessary to completely sterilize the
sample. This MTB screening assay is able to use a larger volume of
sputum (1 ml) which is fully homogenized by treatment with SDS
and proteinase K thus ameliorating sampling error. Although it was
not explicitly demonstrated in this study, the 95 C incubation step
reduces the biosafety hazard to the test operator by fully lysing the
bacteria and melting the double stranded DNA to prepared for the
subsequent sequence speciﬁc capture step. This method is not
reliant on a BSL-3 facility thereby expanding its potential to be
applied in limited-resource settings or even at the patient point-of-
care, nor is it reliant on centrifugation, therefore improving sensi-
tivity by using both intact and lysed mycobacterial DNA [18] that
would otherwise be discarded in supernatants of centrifugation-
based extraction methods. By using paramagnetic particles (PMP),
the MTB DNA can be extracted from a larger specimen volume, and
the sputum-derived inhibitors can be removed with simple wash
steps. This sputum processing protocol is currently being adapted
J.L. Reed et al. / Tuberculosis 101 (2016) 114e124 123so that it may be performed directly in the sputum collection cup,
in order to minimize operator handling and potential for cross-
contamination.
It was recently reported that in patients who have been previ-
ously treated for TB, 1 in 7 Xpert® MTB/RIF-positive results were
false-positive relative to mycobacterial culture in a high incidence
setting [32]. False positives are correlated with a previous infection
that occurred in the last 3 years [33]. The test described here is
designed to lyse all the bacteria before an aliquot is removed to
reduce sampling error and promote safety of the operator. There-
fore, testing the speciﬁcity of this assay with specimens from
recently recovered TB patients must be carefully evaluated. The test
was designed to have a high negative predictive value so that it can
be used to rule out a TB diagnosis. Additional algorithms designed
to determine if a patient has been treated for TB in the past 3 years
could be used to increase the speciﬁcity of the test in previously
infected patients [32,33].
This study also lends merit to the use of speciﬁc capture based
DNA extraction in other applications of clinical diagnostics and in
other clinical sample types where target DNA may be underrep-
resented relative to a large pool of human DNA or other potential
assay inhibitors. Compared to the two other common sputum
processing and DNA extraction methods discussed here (NALC or
GuHCl treatment with bulk DNA extraction), while speciﬁc capture
based DNA extraction resulted in an equivalent level of MTB-
speciﬁc IS6110 copies, there was a signiﬁcant reduction (2.5e3.7
log copies b-globulin DNA) in co-eluted human genomic DNA.
When tested on a panel of TB positive and negative clinical sputa,
showed a sensitivity of 88.9e96.3% for senX3-regX3 and IS6110,
respectively relative to Xpert® MTB/RIF, with 100% speciﬁcity in
both targets. The assay now requires further validation using
samples that test culture-positive, Xpert® MTB/RIF negative to
determine whether the clinical accuracy exceeds that of Xpert®
MTB/RIF.
The WHO Millennium Development Goal of stopping the in-
crease of TB incidence and halving the TB-associated mortality
by 2015 was achieved globally, but not in Africa [1,34]. The next
goal set by WHO is to eliminate TB by 2050. This will require a
reduction of TB of 16% per year compared to the current rate of
1% per year. In order to achieve these goals, major advances in
diagnostics, vaccines and social policy are required [35].
Increasing diagnostic sensitivity is capable of dramatically
reducing delays in diagnosis and treatment, and it has been
estimated that every 10% increase in test sensitivity can reduce
diagnostic delays experienced by patients by 3e5 days [36].
However, without a combinatorial approach, the success of even
a promising TB diagnostic test is not likely to impart a signiﬁcant
impact in high burden settings. In particular, a highly sensitive
assay is required to reduce reliance on empiric treatment and
improve detection in highly vulnerable populations such as
children and people living with HIV. Speciﬁcally, this will require
targeted development of diagnostic tests designed to address the
challenges of MTB including the intrinsic properties of difﬁcult
clinical sample types that may limit diagnostic assay perfor-
mance, and barriers of implementation in settings with high HIV
and TB incidence.Acknowledgements
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